Bio-Rad Laboratories, Inc. (BIO): Price and Financial Metrics
Bio-Rad Laboratories, Inc. (BIO)
Today's Latest Price: $467.49 USD
Updated Jul 8 4:10pm
Add BIO to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 58 in Medical - Diagnostics/Research
See all "A" rated Strong Buy stocks
BIO Stock Summary
- BIO has a higher market value than 88.63% of US stocks; more precisely, its current market capitalization is $13,800,032,088.
- Bio-Rad Laboratories Inc's stock had its IPO on January 1, 1986, making it an older stock than 92.91% of US equities in our set.
- Over the past twelve months, BIO has reported earnings growth of 156.83%, putting it ahead of 92.4% of US stocks in our set.
- Stocks that are quantitatively similar to BIO, based on their financial statements, market capitalization, and price volatility, are XYL, SNN, RDY, CERN, and TFX.
- Visit BIO's SEC page to see the company's official filings. To visit the company's web site, go to www.bio-rad.com.
BIO Stock Price Chart Technical Analysis Charts
BIO Price/Volume Stats
| Current price | $467.49 | 52-week high | $497.42 |
| Prev. close | $468.34 | 52-week low | $303.82 |
| Day low | $464.01 | Volume | 170,266 |
| Day high | $473.25 | Avg. volume | 258,842 |
| 50-day MA | $457.72 | Dividend yield | N/A |
| 200-day MA | $387.54 | Market Cap | 13.86B |
Bio-Rad Laboratories, Inc. (BIO) Company Bio
Bio-Rad Laboratories manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The company was founded in 1952 and is based in Hercules, California.
BIO Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $467.49 | $192.28 | -59% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Bio-Rad Laboratories Inc. To summarize, we found that Bio-Rad Laboratories Inc ranked in the 27th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 58.5%. As for the metrics that stood out in our discounted cash flow analysis of Bio-Rad Laboratories Inc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 88.91 -- which is good for besting 94.02% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
- The business' balance sheet reveals debt to be 4% of the company's capital (with equity being the remaining amount). Approximately just 13.08% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- BIO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 48.71% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -60% |
| 1% | -59% |
| 2% | -59% |
| 3% | -58% |
| 4% | -58% |
| 5% | -57% |
NUVA, LCI, PKI, GTS, and HOLX can be thought of as valuation peers to BIO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...